Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | PRCP | P42785 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | DRD1 | P21728 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL878428 | 0.78 | PRCP (0.59) | PRCPALDH1A1KDM4ETSHR | |
| SCHEMBL1167895 | 0.77 | PRCP (0.42) | CYP2D6CYP3A4MEN1KMT2APRCP | |
| SCHEMBL3111967 | 0.74 | PRCP (0.43) | CYP2D6CYP3A4MEN1KMT2APRCP | |
| SCHEMBL27896744 | 0.74 | PRCP (0.40) | CYP2D6CYP3A4MEN1KMT2APRCP | |
| SCHEMBL1567832 | 0.73 | HTR2A (0.46) | CYP2D6CYP3A4MEN1KMT2ACHRNB2 | |
| SCHEMBL7257552 | 0.73 | CYP2D6 (0.41) | CYP2D6CYP3A4MEN1KMT2ACHRNB2 | |
| SCHEMBL2275751 | 0.73 | CYP2D6 (0.41) | CYP2D6CYP3A4MEN1KMT2ACHRNB2 | |
| SCHEMBL359803 | 0.73 | CHRNB2 (0.44) | CYP2D6CYP3A4MEN1KMT2ACHRNB2 | |
| SCHEMBL1566232 | 0.73 | PNMT (0.42) | CYP2D6CYP3A4MEN1KMT2ACHRNB2 | |
| SCHEMBL6702423 | 0.73 | PNMT (0.42) | CYP2D6CYP3A4MEN1KMT2ACHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3436432-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2019-02-06 | — | — | EP | claimed |
| WO-2017172802-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-10-05 | — | — | WO | claimed |
| EP-3074377-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2016-10-05 | — | — | EP | claimed |
| WO-2015078374-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2015-06-04 | — | — | WO | claimed |
| US-8927546-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2015-01-06 | — | — | US | claimed |
| EP-2643000-A2 | THERAPEUTIC PIPERAZINES | Dart Neuroscience (Cayman) Ltd (KY) | 2013-10-02 | — | — | EP | claimed |
| WO-2012040258-A2 | THERAPEUTIC PIPERAZINES | HELICON THERAPEUTICS, INC. (US) | 2012-03-29 | — | — | WO | claimed |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-03-17 | — | — | US | claimed |
| US-20090111865-A1 | Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | claimed |
| US-7517898-B2 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2009-04-14 | — | — | US | claimed |
| CN-1726194-A | Novel compound | ASTRAZENECA AB (SE) | 2006-01-25 | — | — | CN | claimed |
| EP-1554254-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2005-07-20 | — | — | EP | claimed |
| WO-2004108689-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | WO | claimed |
| WO-2004108712-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | WO | claimed |
| WO-2004108688-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | WO | claimed |
| US-20040116465-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-06-17 | — | — | US | claimed |
| CN-1503787-A | Novel compounds | — | 2004-06-09 | — | — | CN | claimed |
| WO-2004035548-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-04-29 | — | — | WO | claimed |
| EP-1390350-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-02-25 | — | — | EP | claimed |
| WO-2002085866-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2002-10-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111865-A1 | Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof | H1-3, H1-4, CYP3A4 | CYP2D6 27/4885CYP3A4 3/4885MEN1 2990/4885 |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE4D | CYP2D6 3447/4885CYP3A4 754/4885MEN1 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.